Registry Study Design Presented at the Preventive Cardiovascular Nurses Association 2026 Cardiovascular Nursing Symposium ...
Incyclix Bio, LLC, a cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the ...
About 2 million Americans have a heart condition called “ paroxysmal supraventricular tachycardia ,” or PSVT. An electrical ...
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development of commercialization of innovative cardiovascular medicines, today announced that management will ...
Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.
MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance ...
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 123,000 options (the “Options”) to ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) announced that CARDAMYST, the first and only FDA-approved self-administered treatment for adults with paroxysmal supraventricular tachycardia, is now ...
CARDAMYST is now conveniently available to patients through retail pharmacies National sales force hired with promotional launch in mid-February Expected $25 copay cap for eligible commercially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results